

Buruli ulcer: cured by 8 weeks of oral antibiotics?



In 1998, at a special WHO conference on Buruli ulcer held in Yamoussoukro, Côte d'Ivoire, delegates and heads of state of affected countries recognised Buruli ulcer as a damaging disease about which little was known. Importantly, there seemed to be no reliable chemotherapy, leaving wide excisional surgery and grafting as the only effective treatment.¹ Buruli ulcer is caused by *Mycobacterium ulcerans*—an environmental pathogen with a unique virulence determinant—a potent locally acting toxin. Clinically, Buruli ulcer is a destructive infection of the skin and soft tissue, which can result in severe tissue destruction followed by scarring and contracture. It affects healthy people of all ages, but in Africa mostly children and adolescents because of the young population. Although recorded in 33 countries, Buruli ulcer is of particular concern in certain regions of Africa and Australia.²

In *The Lancet*, Richard Phillips and colleagues³ report an open-label, non-inferiority, phase 3 randomised trial, which is the culmination of a journey WHO began in 1998. The trial compared the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8) with the WHO provisionally recommended standard of oral rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8). 297 people with PCR-confirmed Buruli lesions (≤ 10 cm in diameter) in Ghana and Benin were randomly assigned; median age was 14 years (IQR 10–29) and 153 (52%) participants were female. The primary endpoint was lesion healing without recurrence at 52 weeks. In the RS8 group, the primary endpoint was met in 144 (95%, 95% CI 91–98) of 151 participants compared with 140 (96%, 91–99) of 146 in the RC8 group, establishing non-inferiority of the newer fully oral regimen. Surgery was not required for cure and only four patients (two in each study group) required skin grafts to repair defects. Both regimens were generally well tolerated, but RS8 was associated with eight cases of otovestibular toxicity compared with only one case in the RC8 group. No residual functional limitation was seen in either group at 52 weeks.

The headline finding of the trial is clear and promising: Buruli ulcer was curable with an 8-week course of oral antibiotics and surgery was not required in these patients. So how did this radical change in treatment

approach come about? *M ulcerans* is related to *Mycobacterium marinum*, *Mycobacterium tuberculosis*, and *Mycobacterium leprae*, which are all susceptible to antimycobacterial antibiotics, so it was curious that *M ulcerans* appeared not to be, at least in early field studies.⁴ Part of the reason for this perception might have been paradoxical worsening of the appearance of lesions during treatment.^{5,6} However, a key pilot study sponsored by WHO in a small group of people in Ghana with early Buruli lesions⁷ showed that rifampicin and streptomycin could microbiologically sterilise early Buruli lesions, leading to provisional WHO advice for the medical management of Buruli ulcer.⁸ Experience built confidence in this regimen⁹ and some centres in Africa also reported promising results when oral rifampicin was combined with oral clarithromycin, sometimes without any surgery being required.¹⁰ In Australia, intramuscular streptomycin was not used, but it became apparent that rifampicin-based fully oral regimens reduced relapse after surgery^{11,12} and could often replace surgery as definitive treatment.^{13,14}

Now, Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of Buruli ulcer everywhere. However, this finding does not mean that Buruli ulcer is cured at 8 weeks. Healing of Buruli lesions is

Published Online
March 12, 2020
[https://doi.org/10.1016/S0140-6736\(20\)30478-5](https://doi.org/10.1016/S0140-6736(20)30478-5)
See [Articles](#) page 1259



a slow process. In the study by Phillips and colleagues, the median time to healing was 24 weeks (IQR 8–28) for RS8 and 16 weeks (IQR 8–25) for RC8. Practically, this result means that Buruli lesions are typically not healed at the completion of 8 weeks of antibiotics and it is important for clinicians to understand this. Frequent dressings, support, and reassurance, and, in selected cases, limited surgical debridement or grafting might still be needed.¹⁵ However, we now know that we can trust oral antibiotics for Buruli ulcer, even if this might not be clinically apparent at 8 weeks.

One of the limitations of the study is that the study did not enrol the originally planned number of participants because of slow recruitment, reflecting a general reduction in the incidence of Buruli ulcer in west Africa for reasons that are not clear. Questions remain as to whether we need 8 weeks of treatment or if 4–6 weeks might be sufficient in some cases, whether steroids could reduce inflammatory reactions and improve outcomes, and whether 2 weeks of some of the new antimycobacterial agents in development could suffice.¹⁶ The change in incidence in time and place of Buruli ulcer makes it hard to study and it is a tribute to all involved in this trial that they saw it through, providing clinicians with the key evidence needed to assist people with Buruli ulcer to resume their lives and to put the disease behind them.

I declare no competing interests.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Paul D R Johnson

paul.johnson@austin.org.au

Infectious Diseases Department, Austin Health, and University of Melbourne, Heidelberg, VIC 3084, Australia

- 1 WHO, Department of Disease Control, Prevention and Eradication. Buruli ulcer: management of *Mycobacterium ulcerans* disease: a manual for health care providers. Geneva: World Health Organization, 2001. https://www.who.int/buruli/resources/who_cds_cpe_gbui_2001.3/en/ (accessed Feb 15, 2020).
- 2 Omansen TF, Erbowor-Becksen A, Yotsu R, et al. Global epidemiology of Buruli ulcer, 2010–2017, and analysis of 2014 WHO programmatic targets. *Emerg Infect Dis* 2019; **25**: 2183–90.
- 3 Phillips RO, Robert J, Abass KM, et al. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. *Lancet* 2020; published online March 12. [https://doi.org/10.1016/S0140-6736\(20\)30047-7](https://doi.org/10.1016/S0140-6736(20)30047-7).
- 4 Espey DK, Djomand G, Diomande I, et al. A pilot study of treatment of Buruli ulcer with rifampin and dapsone. *Int J Infect Dis* 2002; **6**: 60–65.
- 5 O'Brien DP, Robson ME, Callan PP, McDonald AH. "Paradoxical" immune-mediated reactions to *Mycobacterium ulcerans* during antibiotic treatment: a result of treatment success, not failure. *Med J Aust* 2009; **191**: 564–66.
- 6 Nienhuis WA, Stienstra Y, Abass KM, et al. Paradoxical responses after start of antimicrobial treatment in *Mycobacterium ulcerans* infection. *Clin Infect Dis* 2012; **54**: 519–26.
- 7 Etuaful S, Carbone B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of *Mycobacterium ulcerans* in early lesions of Buruli ulcer in humans. *Antimicrob Agents Chemother* 2005; **49**: 3182–86.
- 8 WHO. Role of specific antibiotics in *Mycobacterium ulcerans* (Buruli ulcer) management provisional guidelines. 2004. <https://www.who.int/buruli/information/antibiotics/en/> (accessed Feb 15, 2020).
- 9 Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (*Mycobacterium ulcerans* disease). *Antimicrob Agents Chemother* 2007; **51**: 4029–35.
- 10 Chauty A, Ardant MF, Marsollier L, et al. Oral treatment for *Mycobacterium ulcerans* infection: results from a pilot study in Benin. *Clin Infect Dis* 2011; **52**: 94–96.
- 11 O'Brien DP, McDonald A, Callan P, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of *Mycobacterium ulcerans*: an observational cohort study. *PLoS Negl Trop Dis* 2012; **6**: e1473.
- 12 Jenkin GA, Smith M, Fairley M, Johnson PD. Acute, oedematous *Mycobacterium ulcerans* infection in a farmer from far north Queensland. *Med J Aust* 2002; **176**: 180–81.
- 13 Friedman ND, Athan E, Hughes AJ, et al. *Mycobacterium ulcerans* disease: experience with primary oral medical therapy in an Australian cohort. *PLoS Negl Trop Dis* 2013; **7**: e2315.
- 14 Gordon CL, Buntine JA, Hayman JA, et al. All-oral antibiotic treatment for Buruli ulcer: a report of four patients. *PLoS Negl Trop Dis* 2010; **4**: e770.
- 15 Wadagni AC, Barogui YT, Johnson RC, et al. Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial. *Lancet Infect Dis* 2018; **18**: 650–56.
- 16 Converse PJ, Almeida DV, Tyagi S, Xu J, Nuermberger EL. Shortening Buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting *Mycobacterium ulcerans* gene decay. *Antimicrob Agents Chemother* 2019; **63**: e00426–19.



Treatment of upper urinary tract urothelial carcinoma

Published Online
 March 5, 2020
[https://doi.org/10.1016/S0140-6736\(20\)30519-5](https://doi.org/10.1016/S0140-6736(20)30519-5)
 See [Articles](#) page 1268

Upper tract urothelial (transitional cell) carcinoma (UTUC) is a rare malignant disease occurring in roughly two people per 100 000 population. UTUCs comprise 5–10% of urothelial carcinomas overall.¹ A paucity of dedicated high-level evidence has led to extrapolation from studies of urothelial bladder cancer to establish treatment recommendations. Although UTUC biology and clinical features overlap with those of urothelial bladder cancer, differences exist in gene alteration patterns (eg, *FGFR3* and *HRAS* are more frequently

altered in UTUC whereas *TP53*, *RB1*, and *ERBB2* are less frequently mutated), clinical stage at presentation (higher stage at presentation, on average, for patients with UTUC), gender differences (a higher percentage of women get UTUC, although in terms of total numbers they are still in a minority compared with men), and stage-for-stage outcomes (prognosis is poorer for patients with UTUC).^{2,3} As with many rare disease settings, patients with UTUC are disenfranchised because dedicated research is challenging.